Gymnotic uptake of AntimiRs alter microRNA-34a levels in 2D and 3D epithelial cell culture.

AMO MT: Oligonucleotides: Therapies and Applications antimiRs epithelium imaging lung miR-34a miRNA therapeutic oligonucleotides

Journal

Molecular therapy. Nucleic acids
ISSN: 2162-2531
Titre abrégé: Mol Ther Nucleic Acids
Pays: United States
ID NLM: 101581621

Informations de publication

Date de publication:
12 Sep 2023
Historique:
received: 24 03 2023
accepted: 14 08 2023
medline: 8 9 2023
pubmed: 8 9 2023
entrez: 8 9 2023
Statut: epublish

Résumé

MicroRNAs are attractive therapeutic targets in many diseases, including chronic obstructive pulmonary disease and idiopathic pulmonary fibrosis. Among microRNA inhibitors antimiRs have been proven successful in lowering aberrant microRNA levels in the clinic. We present a set of antimiRs targeting miR-34a, which has been shown to be dysregulated in chronic lung diseases. The tool compounds were taken up by a bronchial epithelial cell line and primary human bronchial epithelial cells, followed by efficient knockdown of miR-34a. Similar results were observed in 3D differentiated primary human bronchial epithelial cells cultured at the air-liquid interface. Varying chemical properties of antimiRs had significant impact on cellular uptake and potency, resulting in effective tool compounds for use in lung-relevant cellular systems. This report demonstrates gymnotic antimiR uptake and activity in 3D epithelial cell culture after apical administration, mimicking inhalation conditions.

Identifiants

pubmed: 37680982
doi: 10.1016/j.omtn.2023.08.014
pii: S2162-2531(23)00224-X
pmc: PMC10480572
doi:

Types de publication

Journal Article

Langues

eng

Pagination

898-907

Informations de copyright

© 2023 The Authors.

Déclaration de conflit d'intérêts

All authors are AstraZeneca employees.

Références

Oncotarget. 2017 May 30;8(22):35609-35618
pubmed: 28415675
Nucleic Acids Res. 2006 May 11;34(8):2294-304
pubmed: 16690972
Future Med Chem. 2014;6(17):1967-84
pubmed: 25495987
Nucleic Acids Res. 2018 Nov 16;46(20):10905-10916
pubmed: 30169779
Nucleic Acid Ther. 2014 Dec;24(6):374-87
pubmed: 25353652
Nucleic Acid Ther. 2019 Oct;29(5):245-255
pubmed: 31158063
Biochem Pharmacol. 2019 Jan;159:106-115
pubmed: 30452907
Angew Chem Int Ed Engl. 2019 May 13;58(20):6611-6615
pubmed: 30884043
Drug Discov Today. 2018 Jan;23(1):101-114
pubmed: 28988994
Mol Ther Nucleic Acids. 2020 Mar 6;19:706-717
pubmed: 31951854
Sci Rep. 2016 Oct 21;6:35871
pubmed: 27767101
Bioconjug Chem. 2012 Feb 15;23(2):147-57
pubmed: 21992697
Nat Biotechnol. 2017 Mar;35(3):238-248
pubmed: 28244990
Histochem Cell Biol. 2018 Aug;150(2):107-118
pubmed: 29774430
Biochim Biophys Acta Biomembr. 2020 Feb 1;1862(2):183145
pubmed: 31809710
Nucleic Acid Ther. 2023 Aug 29;:
pubmed: 37643307
Nucleic Acids Res. 2014 Jan;42(1):609-21
pubmed: 24068553
Silence. 2012 Jan 09;3(1):1
pubmed: 22230293
Cell Res. 2012 May;22(5):793-805
pubmed: 22525333
Nucleic Acids Res. 2002 May 1;30(9):1911-8
pubmed: 11972327
Angew Chem Int Ed Engl. 2021 Aug 23;60(35):19102-19106
pubmed: 34173696
Nat Struct Mol Biol. 2012 Jun 05;19(6):586-93
pubmed: 22664986
Trends Genet. 2022 Jun;38(6):613-626
pubmed: 35303998
Nature. 2005 Dec 1;438(7068):685-9
pubmed: 16258535
Cells. 2020 Jan 07;9(1):
pubmed: 31936122
Nat Genet. 2011 Mar 20;43(4):371-8
pubmed: 21423181
Front Immunol. 2021 Jan 08;11:608666
pubmed: 33488613
Int J Mol Sci. 2019 Aug 13;20(16):
pubmed: 31412612
J Med Chem. 2016 Nov 10;59(21):9645-9667
pubmed: 27434100
Gene Ther. 2011 Dec;18(12):1111-20
pubmed: 21753793
PLoS One. 2014 Feb 04;9(2):e87649
pubmed: 24503716
Pharmaceutics. 2022 Jan 22;14(2):
pubmed: 35213992
Proc Natl Acad Sci U S A. 2008 Sep 9;105(36):13421-6
pubmed: 18755897
Int J Mol Sci. 2020 Apr 16;21(8):
pubmed: 32316149
PLoS One. 2020 Jan 3;15(1):e0227174
pubmed: 31900469
Pharm Res. 2010 Sep;27(9):1788-99
pubmed: 20424893
Am J Physiol Lung Cell Mol Physiol. 2017 Mar 01;312(3):L415-L424
pubmed: 27979858
J Adv Res. 2020 Aug 29;28:127-138
pubmed: 33364050
Cell. 2018 Mar 22;173(1):20-51
pubmed: 29570994
Adv Nanobiomed Res. 2021 May 06;1(6):
pubmed: 34345878
Am J Respir Cell Mol Biol. 2017 Feb;56(2):168-178
pubmed: 27635790
RNA Biol. 2018 Mar 4;15(3):338-352
pubmed: 29570036
Nat Rev Drug Discov. 2019 Jun;18(6):421-446
pubmed: 30846871
Cell. 2004 Jan 23;116(2):281-97
pubmed: 14744438
Nature. 2008 Apr 17;452(7189):896-9
pubmed: 18368051
Sci Adv. 2018 Oct 17;4(10):eaat3386
pubmed: 30345352
Nucleic Acids Res. 2017 Jan 9;45(1):15-25
pubmed: 27899655
Pharmacol Res. 2020 Oct;160:105045
pubmed: 32590100
FEBS J. 2018 Dec;285(23):4343-4358
pubmed: 29896776

Auteurs

Julie Weidner (J)

Translational Science Experimental Medicine, Research & Early Development, Respiratory & Immunology, BioPharmaceutical R&D, AstraZeneca, 431 83 Mölndal, Sweden.

Ewa Kolosionek (E)

Bioscience COPD/IPF, Research & Early Development, Respiratory & Immunology, BioPharmaceutical R&D, AstraZeneca, 431 83 Mölndal, Sweden.

Reetta Holmila (R)

Bioscience COPD/IPF, Research & Early Development, Respiratory & Immunology, BioPharmaceutical R&D, AstraZeneca, 431 83 Mölndal, Sweden.

Elisabeth Ax (E)

Translational Science Experimental Medicine, Research & Early Development, Respiratory & Immunology, BioPharmaceutical R&D, AstraZeneca, 431 83 Mölndal, Sweden.

Marion Garreau (M)

Medicinal Chemistry, Research & Early Development, Respiratory & Immunology, BioPharmaceutical R&D, AstraZeneca, 431 83 Mölndal, Sweden.

Felix Gnerlich (F)

Medicinal Chemistry, Research & Early Development, Respiratory & Immunology, BioPharmaceutical R&D, AstraZeneca, 431 83 Mölndal, Sweden.

Henric Olsson (H)

Translational Science Experimental Medicine, Research & Early Development, Respiratory & Immunology, BioPharmaceutical R&D, AstraZeneca, 431 83 Mölndal, Sweden.

Werngard Czechtizky (W)

Medicinal Chemistry, Research & Early Development, Respiratory & Immunology, BioPharmaceutical R&D, AstraZeneca, 431 83 Mölndal, Sweden.

Stefan Vollmer (S)

Bioscience COPD/IPF, Research & Early Development, Respiratory & Immunology, BioPharmaceutical R&D, AstraZeneca, 431 83 Mölndal, Sweden.

Anna M Rydzik (AM)

Medicinal Chemistry, Research & Early Development, Respiratory & Immunology, BioPharmaceutical R&D, AstraZeneca, 431 83 Mölndal, Sweden.

Classifications MeSH